Concepedia

Shilpi Khare

SK

Statistics

Publications

2

Citations

126

H-Index

2

Active since

2022

Affiliations

Mirati Therapeutics (United States)(Current)

Shilpi Khare is an author at Mirati Therapeutics (United States) specializing in cancer pharmacology, drug discovery, and pharmacology.

ORCID

Publications per year

2022–2024

2

Publications

2

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction

John M. Ketcham, Jacob R. Haling, Shilpi Khare et al. · Journal of Medicinal Chemistry · 2022 · 94 citations · Full text

, , +11

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos et al. · Molecular Cancer Therapeutics · 2024 · 32 citations · Full text

, , +14

1–2 of 2